API
< Back to situation

[REVISION HISTORY]

Brazil plans semaglutide integration into SUS

32 recorded revisions of this situation.

What changed

2026-11-10 19:53 UTC → 2026-11-10 23:04 UTC · added removed

The Brazilian Ministry of Health is progressing with plans to incorporate semaglutide-based weight-loss medications into the Unified Health System (SUS). On September 24, 2026, the Ministry submitted a formal request to the National Commission for the Incorporation of Technologies in the SUS (Conitec) to establish clinical protocols. The initiative, which aligns with President Lula’s reelection campaign promises, aims to serve millions of patients, targeting obesity, a condition affecting approximately 25% of the population. The Ministry estimates an annual investment of R$ 1.5 billion, suggesting that bulk purchasing could lead to government discounts of up to 90%. To prevent ‘purely aesthetic purposes,’ the program will prioritize high-risk individuals, such as those awaiting bariatric surgery or those with obesity-related comorbidities like heart disease. A pilot study, Real-Bari, is currently monitoring 250 patients in Porto Alegre to establish safety guidelines. On October 27, 2026, Anvisa approved the registration of five new GLP-1 receptor agonist pens: Aribet, Lyrza, Wylovol, Embeltah, and Sevema. On November 4, 2026, Anvisa approved the oral tablet version of Wegovy, marking the first authorized oral GLP-1 receptor agonist in Brazil. Expanding on these regulatory developments, Anvisa approved two new injectable semaglutide medications, a generic version and a similar product named Loryvia, registered by Ávita Care Importação e Distribuição de Produtos Ltda. These products follow the recent patent expiration of Ozempic and aim to increase the national supply of GLP-1 receptor agonists, a priority for the Ministry of Health. Concurrently, Anvisa ordered the seizure of the unregistered weight-loss product Ultra Shape by Ciência da Natureza, along with various unauthorized supplements and cleaning products sold on e-commerce platforms. On November 9, 2026, Anvisa expanded its regulatory actions, noting that the total number of registered GLP-1 receptor agonist pens reached 22 in 2026.

Versions

  1. 2026-11-10 23:04 UTC Brazil plans semaglutide integration into SUS
  2. 2026-11-10 19:53 UTC Brazil plans semaglutide integration into SUS
  3. 2026-11-06 06:26 UTC Brazil plans semaglutide integration into SUS
  4. 2026-11-05 22:06 UTC Brazil plans semaglutide integration into SUS
  5. 2026-11-04 23:59 UTC Brazil plans semaglutide integration into SUS
  6. 2026-11-04 16:22 UTC Brazil plans semaglutide integration into SUS
  7. 2026-11-04 14:50 UTC Brazil plans semaglutide integration into SUS
  8. 2026-11-04 11:18 UTC Brazil plans semaglutide integration into SUS
  9. 2026-10-29 17:08 UTC Brazil plans semaglutide integration into SUS
  10. 2026-10-29 16:26 UTC Brazil plans semaglutide integration into SUS
  11. 2026-10-28 00:02 UTC Brazil plans semaglutide integration into SUS
  12. 2026-10-24 17:15 UTC Brazil plans semaglutide integration into SUS
  13. 2026-10-12 23:34 UTC Brazil plans semaglutide integration into SUS
  14. 2026-10-03 12:34 UTC Brazil plans semaglutide integration into SUS
  15. 2026-10-02 02:53 UTC Brazil plans semaglutide integration into SUS
  16. 2026-10-01 21:23 UTC Brazil plans semaglutide integration into SUS
  17. 2026-09-29 18:12 UTC Brazil plans semaglutide integration into SUS
  18. 2026-09-26 16:41 UTC Lula healthcare and reelection discussions in Brazil
  19. 2026-09-25 21:28 UTC Lula healthcare and reelection discussions in Brazil
  20. 2026-09-25 17:48 UTC Lula healthcare and reelection discussions in Brazil
  21. 2026-09-25 15:08 UTC Lula healthcare and reelection discussions in Brazil
  22. 2026-09-24 23:14 UTC Lula healthcare and reelection discussions in Brazil
  23. 2026-09-20 23:45 UTC Lula healthcare and reelection discussions in Brazil
  24. 2026-09-19 16:12 UTC Lula healthcare and reelection discussions in Brazil
  25. 2026-09-19 13:21 UTC Lula healthcare and reelection discussions in Brazil
  26. 2026-09-19 03:57 UTC Lula healthcare and reelection discussions in Brazil
  27. 2026-09-18 21:30 UTC Lula healthcare and reelection discussions in Brazil
  28. 2026-09-18 21:30 UTC Lula healthcare and reelection discussions in Brazil
  29. 2026-09-18 20:04 UTC Lula healthcare and reelection discussions in Brazil
  30. 2026-09-18 17:26 UTC Lula healthcare and reelection discussions in Brazil
  31. 2026-09-18 14:24 UTC Lula healthcare and reelection discussions in Brazil
  32. 2026-09-18 02:53 UTC Lula healthcare and reelection discussions in Brazil
  33. 2026-09-17 23:41 UTC Lula healthcare and reelection discussions in Brazil

Select a version to see what changed compared to the one before it.